Compare Abeona Therapeutics Inc (ABEO) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Alnylam Pharmaceuticals, Inc. trades at $324.34 (market cap $42.94B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 115× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | ALNY | |
|---|---|---|
Market Cap | $373.32M | $42.94B |
Sector | Health | Health |
52-Week High | $7.23 | $491.22 |
52-Week Low | $4.17 | $278.09 |
Enterprise Value | $228.22M | $41.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Alnylam Pharmaceuticals (ALNY) trades at $321.59, up 2.82% today, with a bullish technical signal supported by moving averages. The company reported strong revenue growth, reaching $3.71 billion in 2025, and turned profitable with net income of $313.75 million. Recent news highlights its AI partnerships and expanding drug pipeline as key growth drivers.
The outlook is positive, with a consensus price target of $435.40 implying 35% upside, driven by robust revenue growth and pipeline advancements. Risks include dependence on key drug Amvuttra and high valuation multiples. Analyst sentiment is strongly bullish, with 75% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
